Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
Precigen, Inc., a Virginia corporation, filed this Current Report on Form 8-K on August 10, 2020. The filing serves to disclose the company's financial results for the quarter ended June 30, 2020, via an attached press release (Exhibit 99.1). The company's common stock trades on the Nasdaq Global Select Market under the symbol PGEN.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) and non-GAAP reconciliation (Exhibit 99.3), which are referenced but not included in the source text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2020, have been reported.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure: The company provided a slide presentation (Exhibit 99.2) to accompany the press release.
- Non-GAAP Measures: A reconciliation of a non-GAAP financial measure is included as Exhibit 99.3.
- Legal Status: The information in the press release and exhibits is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2020 revenue, net loss, and cash burn figures.
- Examine Exhibit 99.3 to understand the adjustments made to reconcile GAAP to non-GAAP metrics.
- Consult the slide presentation (Exhibit 99.2) for management's commentary on clinical progress and future outlook.
- Verify the company's current cash position and runway based on the detailed financial statements referenced in the press release.